C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
C4 Therapeutics, Inc. (CCCC) is a Biotechnology company based in US with a market capitalization of $317.2M. Revenue grew 1.0% year-over-year and free cash flow was negative at -$99.3M. This page tracks CCCC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 110 employees · IPO Oct 2, 2020
Valuation
Valuation & price
$3.56as of May 17, 2026· -23.8% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.24
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$317.2M
Market cap
1.0%
Revenue growth (YoY)
77.8%
Gross margin
-$99.3M
Free cash flow (USD)
-$188.6M
Net debt
Net cash position
19.5%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 24, 2026Filing
Annual Meeting Results
- 8-K eventJun 11, 2026Filing
Collaboration Agreement
- 8-K eventMay 15, 2026Filing
Principal Accounting Officer Change
- 8-K eventMay 12, 2026Filing
Earnings Release
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- 8-K eventApr 10, 2026Filing
By-law Amendment
- 8-K eventApr 9, 2026Filing
Research Collaboration Agreement
Questions
Frequently asked questions
What is C4 Therapeutics, Inc.'s market cap?
C4 Therapeutics, Inc. (CCCC) has a market capitalization of $317.2M.
What is CCCC's P/E ratio?
A meaningful P/E ratio is not available for CCCC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is CCCC's price-to-book (P/B) ratio?
CCCC trades at 1.24 times book value per share.
Are insiders buying CCCC stock?
SEC Form 4 filings show no open-market insider buys at C4 Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.